

Appl. No. : **10/805,386**
Filed : **March 22, 2004**

SUMMARY OF INTERVIEW

Exhibits and/or Demonstrations

None

Identification of Claims Discussed

19, 21-35, and 37-48, i.e., all of the pending claims and the proposed new claims.

Identification of Prior Art Discussed

Lord et al. (USP 6,417,227), WO 00/85162, and Diehl (USP 4,113,881).

Proposed Amendments

Applicants proposed to include a listing of excipients or carriers as a Markush group and a listing of cetylated fatty acids as a Markush group in claim 19.

Principal Arguments and Other Matters

Applicants argued that the art taught away from the use of anti-inflammatory drugs for the treatment of periodontal disease and that there was long felt and unmet need for a useful anti-inflammatory drug, as evidenced by the Van Dyke Declaration (a draft of which was presented to the Examiner). Applicants further argued that the specification provided sufficient enablement for a composition comprising a cetylated fatty acid, selected from the list provided in Table 3 of the specification, and a carrier or excipients, as disclosed in the specification.

Results of Interview

The Examiner suggested that the proposed amendments, in conjunction with the Van Dyke Declaration and Applicants' other arguments, will be looked upon favorably.